- Home
- COYA vs HURA Comparison
COYA vs HURA Comparison
Compare COYA & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COYA | HURA |
|---|---|---|
| Founded | 2020 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.6M | 131.8M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | COYA | HURA |
|---|---|---|
| Price | $4.59 | $0.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $15.80 | $10.00 |
| AVG Volume (30 Days) | ★ 326.8K | 285.2K |
| Earning Date | 03-17-2026 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,987,706.00 | N/A |
| Revenue This Year | $70.00 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.94 | $0.62 |
| 52 Week High | $8.29 | $5.27 |
Technical Indicators
Market Signals| Indicator | COYA | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 23.04 |
| Support Level | $4.51 | $0.68 |
| Resistance Level | $4.82 | $0.68 |
| Average True Range (ATR) | 0.36 | 0.05 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 44.17 | 17.24 |
Price Performance
Historical ComparisonAbout COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.